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Several reviews and guidelines on the management of mycosis fungoides and Se´zary
syndrome (MF/SS) have been published; however, treatment strategies for patients with
MF/SS vary from institution to institution and no European consensus has yet been
established. There are few phase III trials to support treatment decisions for MF/SS
and treatment is often determined by institutional experience. In order to summarise
the available evidence and review ‘best practices’ from each national group, the Euro-
pean Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma
Task Force met in September 2004 to establish European guidelines for the treatment of
MF/SS.
This article reviews the treatment regimens selected for inclusion in the guidelines
and summarises the clinical data for treatments appropriate for each stage of MF/SS.
Guideline recommendations are presented according to the quality of supporting data, as
defined by the Oxford Centre for Evidence-Based Medicine. Skin-directed therapies areer Ltd. All rights reserved.
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Photochemotherapy
Chemotherapy
Immunotherapy
Biological response modifiers
Retinoids
Corticosteroidsm EORTC Guidelines Workshop for the man
Fungoides/Se´zary Syndrome. EORTC Cutane
Force Meeting, Madrid, Spain, 24 Septemberthe most appropriate option for early-stage MF/SS and most patients can look forward to a
normal life expectancy. Patients with advanced disease should be encouraged to partici-
pate in clinical trials and maintenance of quality of life should be paramount.
 2006 Elsevier Ltd. All rights reserved.1. Introduction
Cutaneous lymphomas are a group of disorders characterised
by localisation of malignant lymphocytes to the skin. Approx-
imately two-thirds of these lymphomas are of T-cell origin,
and the pathogenesis and management of both T- and B-cell
cutaneous lymphomas have been recently reviewed.1–6 The
most common form of cutaneous T-cell lymphoma (CTCL) is
mycosis fungoides (MF), accounting for around 60% of new
cases. Se´zary syndrome (SS) is much rarer and accounts for
only 5% of CTCL cases.3,7–9 An analysis of US cancer registries
showed that the incidence of MF/SS increased markedly from
1973 to 1984, with the highest incidence reported in the el-
derly. African-Americans had a twofold higher incidence than
Caucasians: the incidence in men was more than twice than
that observed in women.10 Since 1983 the incidence of MF/SS
appears to have stabilised at 0.36 per 105 person-years, and
the mortality rate has declined.11 Age-adjusted incidence, rel-
ative to Caucasians, is 1.7 for African-Americans and 0.6 for
Asians.11 In Europe, according to the Finnish Cancer Registry
Database, the incidence of cutaneous T-cell lymphoma has
been reported for the Finnish population to be as high as 2.5
per 105 for men and 1.5 per 105 for women.12
There are many therapeutic options available for the man-
agement of CTCL, including MF/SS.7,13 The choice of treat-
ment is often determined by physician or patient
preference, or institutional experience, particularly as there
is a paucity of data from phase III trials and a lack of consen-
sus concerning treatment for later stages of MF/SS.3,14–16
However, a number of authors have published recommenda-
tions or reviews on the management of CTCL,1,3,7,15,17, and
guidelines have been published jointly by the British Associa-
tion of Dermatologists and the UK Cutaneous Lymphoma
Group.16 Nonetheless, treatment choices vary across Europe
and there are, as yet, no uniform European guidelines for
the management of CTCL.
2. Development process of recommendations
In September 2004, the European Organisation for Research
and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task
Force organised a Workshop meeting to establish a consensus
for the development and implementation of European guide-
lines for the management of MF/SS.1m At the meeting, ‘best
practices’ from each national group were presented for discus-agement of Mycosis
ous Lymphoma Task
2004.sion. Differences between the recommendations from each
country were discussed, and consensus established. This arti-
cle reports the outcomes from the meeting and the resulting
EORTC recommendations for the management of MF/SS. The
recommendations are presented by disease stage and accom-
panied by ‘levels of evidence’ to facilitate interpretation.
3. Classification of CTCL
Primary cutaneous lymphomas often have a different clinical
course to histologically similar systemic lymphomas. There-
fore, the EORTC classification for primary cutaneous lympho-
mas was established in 1997: the World Health Organization
(WHO) classification for tumours of haematopoietic and
lymphoid tissues includes primary cutaneous lymphomas as
separate entities. Remaining differences between the two clas-
sification systems have resulted in the recent publication of the
WHO-EORTC classification of cutaneous lymphomas (Table 1).6
This classification is based primarily on distinct disease enti-
ties with predictable treatment responses and prognoses.
MF is generally an indolent malignancy, with slow progres-
sion over years or even decades.6,7 Conversely, SS, character-
ised by erythroderma, lymphadenopathy and the appearance
of tumour cells in the peripheral blood, is associated with a
median survival of only 32 months from diagnosis.7,16
4. Levels of evidence
Much has been written in recent years on the need for clinical
guidelines and the criteria they should meet for development
and application, as well as evidence and recommendations to
be used in their support.18–20 The levels of evidence used in
this article will be as described by the Oxford Centre for Evi-
dence-Based Medicine (Tables 2a and 2b).20
5. Clinical presentation
The onset of MF is often insidious and initial cutaneous
symptoms may be difficult to distinguish from other non-
malignant pathologies of the skin.7 The median duration
from the initial appearance of skin symptoms to a diagnosis
of MF/SS is almost 6 years.7 Typically, the initial lesions in
MF are flat and erythematous skin patches, which evolve over
a variable period of time into palpable plaques characterised
by well-demarcated edges.7 Patches and plaques may also ex-
hibit hypopigmentation or hyperpigmentation.1 Plaques can
be followed by tumours, although it is common for patients
to have patch, plaque and tumour lesions simultaneously
on different parts of the body.7 The time course of progression
Table 2b – Grades of recommendation20
A Consistent level 1 studies
B Consistent level 2 or 3 studies, or extrapolations from
level 1 studies
C Level 4 studies, or extrapolations from level 2 or 3 studies
D Level 5 evidence, or troublingly inconsistent or inconclusive
studies of any level
Table 3 – Clinical staging for MF1,3,23
(a) Classification
T1 Patches, plaques, or both, involving <10% body surface area
T2 Patches, plaques, or both, involving P10% body surface area
T3 One or more cutaneous tumours
T4 Generalised erythroderma
N0 Lymph nodes clinically uninvolved
N1 Lymph nodes clinically enlarged but not histologically
involved
N2 Lymph nodes clinically non-palpable but histologically
involved
N3 Lymph nodes clinically enlarged and histologically involved
M0 No visceral metastases
M1 Visceral metastases
B0 No circulating atypical cells (Se´zary cells), <5%
B1 Circulating atypical cells (Se´zary cells), P5%
(b) Clinical stages Expected 5-year survival16 (%)
IA T1 N0 M0 96–100
IB T2 N0 M0 73–86
IIA T1–2 N1 M0 49–73
IIB T3 N0–1 M0 40–65
III T4 N0–1 M0 40–57
IVA T1–4 N2–3 M0 15–40
IVB T1–4 N0–3 M1 0–15
SS is staged as T4 N1 or N3 M0 B1.16
Table 2a – Oxford Centre for Evidence-Based Medicine:
levels of evidence20
1a Evidence obtained from systematic reviews of multiple,
randomised, controlled trials (RCTs), with homogeneity
1b Evidence from individual RCT with a narrow
confidence interval
1c All patients died prior to introduction of drug but some
now survive or Some patients died prior to introduction
of drug but all now survive
2a Evidence obtained from systematic reviews of multiple
cohort studies, with homogeneity
2b Evidence from individual cohort study or poor-quality RCT
(<80% follow-up)
2c Evidence obtained from outcomes research
3a Evidence obtained from systematic reviews of multiple
case-control studies with homogeneity
3b Evidence from individual case-control study
4 Evidence from a case series, or poor-quality cohort study,
or poor-quality case-control studies
5 Evidence based on expert opinion without critical appraisal,
or laboratory research, physiology, or ‘first principles’
Table 1 – WHO-EORTC classification for cutaneous T-cell
lymphomas with primary cutaneous manifestations6
MF
MF variants and subtypes:
Folliculotropic MF
Pagetoid reticulosis
Granulomatous slack skin
Se´zary syndrome
Adult T-cell leukaemia/lymphoma
Primary cutaneous CD30-positive lymphoproliferative disorders:
Primary cutaneous anaplastic large cell lymphoma
Lymphomatoid papulosis
Subcutaneous panniculitis-like T-cell lymphoma
Extranodal natural killer/T-cell lymphoma, nasal type
Peripheral cutaneous peripheral T-cell lymphoma, unspecified
Primary cutaneous aggressive epidermotropic CD8+ T-cell
lymphoma (provisional)
Cutaneous a˜/a¨ T-cell lymphoma (provisional)
Primary cutaneous CD4+ small/medium-sized pleomorphic
T-cell lymphoma (provisional)
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able. Tumours are the presenting stage in about 10% of cases
and are characterised by protruding, often ulcerative, lesions
and lymphocytic infiltration into the dermis.1,7 Infection, sec-
ondary to ulceration, is a frequent cause of morbidity.3
Some patients with patch-stage MF will never progress to
other forms of the disease, but many will eventually develop
advanced disease.7 Patients in whom erythema extends to
80% or more of the total skin surface are significantly morelikely to have leukaemic involvement in the peripheral blood.1
SS describes patients with generalised erythroderma and so-
called Se´zary cells in the peripheral blood.1,3 These are en-
larged, atypical lymphocytes with characteristic convoluted
nuclei, which can be found in the peripheral blood of approx-
imately 25% and 10% of patients with cutaneous tumours and
generalised plaques, respectively.1,7 The number of circulat-
ing Se´zary cells required for a diagnosis of SS has been a mat-
ter of debate.3,7 However, the International Society for
Cutaneous Lymphomas has proposed the following criteria
for diagnosis: a Se´zary cell count P1000/lL, CD4/CD8 ratio
P10, an increase in circulating T cells with aberrant marker
expression, and evidence of a T-cell clone in the peripheral
blood.1,8 Histopathology of the skin is similar in MF and SS
and has been described in other studies.1,3,7,21 Histopatholo-
gical diagnosis in early MF may be unreliable unless moder-
ately enlarged lymphocytes with cerebriform nuclei are
present.3,21 Recently, an algorithm for the early diagnosis of
MF was proposed, which is based on clinical, histological,
and ancillary (immunophenotypic, molecular) criteria.22
6. Staging
Staging of MF is based on a tumour–node–metastasis (TNM)
system, originally published in 1979.1,3,7,23 Numerous studies
have shown that prognosis is dependent on the magnitude of
the cutaneous tumour burden.1 Increased skin surface area
involvement is also associated with a poorer prognosis, as is
lymph node involvement and the appearance of clonal T cells
in the peripheral blood.1,7 Table 3a/b shows the TNM classifi-
cation, the resulting stages, and the prognostic implications
in terms of survival.1,16
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cd TCR phenotype, a reduced proportion of CD8-positive lym-
phocytes in tumour infiltrates, transformation to a large-cell
lymphoma, the presence of a T-cell clone in the peripheral
blood, follicular mucinosis, and age >60 years at presenta-
tion.3,7,16,24–28
7. Treatment modalities considered for
inclusion in the consensus recommendations
The aims of treatment for CTCLs include clearance of lesions,
that is, remission, in order to maintain or improve quality of life
and prolong disease-free survival and overall survival.29,30
However, assessing response to treatment is not necessarily
straightforward. MF is an indolent condition with a long natu-
ral history and may not extend beyond the skin for many
years.7 This finding has necessitated the use of surrogate mark-
ers, such as the tumour burden measurements described by
Heald, which can be used to assess the effects of treatment.29
8. Skin-directed therapy
Skin-directed therapy (SDT) comprises one or more of the fol-
lowing: topical corticosteroids, topical nitrogen mustard
(HN2), topical BCNU (carmustine), psoralen plus ultraviolet
(UV)A, UVB, total skin electron beam therapy (TSEB), and
superficial X-irradiation. These treatment options are de-
scribed in the following sections.
8.1. Topical corticosteroids
This therapy has been successfully used in the treatment of
mild, patch-stage MF. Topical corticosteroids target the major-
ity of the tumour burden in the skin by directly inducing
apoptosis of malignant T cells, and can induce complete
clearance of the disease.4 This treatment also decreases the
number of Langerhans cells, thus interrupting the stimula-
tion of malignant T cells.4 Topical corticosteroids can be used
to treat individual skin lesions and are available as lotions,
creams or ointments.
8.2. Topical HN2, mechlorethamine
This medication has no EMEA approval: France and The
Netherlands are the only European countries in which it is
available. Topical HN2 has been used for the treatment of
MF for almost half a century.31 HN2 is applied at 0.01% or
0.02% as either an aqueous or ointment-based formulation;
both formulations appear to have equivalent efficacy.15,32,33
The reported probability of hypersensitivity reactions varies
from less than 10% to as much as 67%, although these are
less likely with the ointment formulation.15,32–35 Therapy is
usually continued for 6 months after the clearance of skin le-
sions.15 HN2 has also been reported to induce repigmentation
in hypopigmented MF lesions.36
8.3. Topical BCNU, carmustine
Topical application is performed with a solution of 10 mg
BCNU dissolved in 60 mL 95% alcohol. Alternatively, a 20–40% ointment can be used.16 Hypersensitivity reactions are
less frequent than with HN2 but regular blood counts should
be performed during topical BCNU treatment to monitor for
bone marrow suppression.16
8.4. Bexarotene gel
Bexarotene gel is a new topical retinoid (‘rexinoid’) with a un-
ique mechanism of action (see below). In a phase I/II study, 42
of 67 patients with stage IA–IIA disease achieved at least a
partial response (PR; P50% improvement), and 21% of pa-
tients achieved a complete response (CR) based on the Physi-
cian’s Global Assessment of skin involvement relative to
baseline.37 Efficacy improved with increases in concentration
and frequency of application.37 Bexarotene gel is generally
well tolerated, with side-effects restricted to the site of appli-
cation. Bexarotene gel was approved by the FDA in June 2000
as therapy for stage IA–IIA CTCL.
8.5. Psoralen plus UVA (320–400 nm) phototherapy
(PUVA)
Psoralen (methoxsalen) is taken up by epidermal cells and
forms bifunctional and monofunctional DNA adducts when
photoactivated.38 The first report of PUVA treatment in MF
was published in 1976.39 Initial UVA doses can be as low as
0.5 J/cm2, but are then increased at each treatment session
until a CR is achieved or the maximum tolerated dose
(MTD) is reached. Treatment regimens vary but, usually,
PUVA is administered 2–4 times per week until skin lesions
have cleared.15 Nausea following 8-methoxypsoralen
(8MOP) ingestion can be avoided by using 5-methoxypsoralen
instead.15 It has been shown in a large prospective trial in
patients with psoriasis that PUVA therapy is associated with
an increased risk of non-melanoma skin cancer.16 A similar
study has not been conducted in patients with MF. In this re-
gard, it should be noted that, although patients with relapsed
disease can be retreated, maintenance therapy rarely pre-
vents relapse and should be avoided in order to minimize
the total dose.16,40
8.6. UVB (broadband 290–320 nm, narrowband
311–312 nm)
In contrast to UVA, use of UVB does not require psoralen
ingestion.15 UVB may also present a lower risk of cutaneous
carcinogenesis than PUVA therapy but may be less effective
in patients with dark skin.15 In addition, narrowband UVB
produces less irritation and erythema than broadband UVB.
A retrospective study of 56 patients with early-stage MF (stage
1A and 1B) suggested that narrowband UVB is at least as
effective, if not more so, than PUVA in terms of response
and relapse-free interval. Narrowband UVB appears to be an
effective treatment for early-stage MF, with advantages over
broadband UVB and PUVA.41
8.7. Total skin electron beam therapy
TSEB is a technically challenging treatment modality that
requires careful attention to dosimetric techniques to avoid
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erated in a linear accelerator and the beam is then attenuated
so that electrons penetrate the skin to a limited depth.7,15 Less
than 5% of the dose extends beyond 2 cm and, for most pa-
tients, the target volume is a skin depth <5 mm: this ensures
that toxicity to the internal organs, including the bone mar-
row, is kept to a minimum.3 MF cells are radiosensitive and
can be effectively killed with low doses of radiation.3,7,16 Use
of TSEB has been extensively reviewed and consensus guide-
lines for the use of TSEB in MF have been published.42,43 The
total treatment dose is usually 30–36 Gy over 8–10 weeks, and
electrons of different energies may be used depending on the
required penetration depth.3,7,16 Patients with MF/SS usually
receive TSEB only once, however, repeat treatments following
relapse have been reported.16,44,45 The EORTC consensus
guidelines recommend that additional courses of TSEB
should be offered only when other appropriate therapies have
failed.43
8.8. Superficial X-irradiation
Localised, superficial radiotherapy provides effective pallia-
tive treatment for individual lesions. Doses used have ranged
from 10 to 30 Gy, and may be fractionated.16,30,46
9. Systemic therapies
Systemic therapies include the following modalities, which
are summarized below: chemotherapy, biological response
modifiers (BRMs), immunotherapy, and extra-corporeal
photoimmunotherapy (ECP).
9.1. Chemotherapy
The chemotherapeutic agents used in MF/SS and discussed in
this article include, among others:
• Methotrexate (MTX): a folate antagonist and inhibitor of de
novo purine and pyrimidine synthesis.
• Gemcitabine: a pyrimidine nucleoside analogue that, after
phosphorylation, inhibits ribonucleotide reductase and
DNA synthesis.
• The CHOP (cyclophosphamide, doxorubicin, vincristine,
and prednisone) combination.47
• Chlorambucil: a nitrogen mustard derivative that is a
bifunctional alkylating agent.
• Liposome-encapsulated doxorubicin: an anthracycline gly-
coside antineoplastic antibiotic. The drug’s precise mecha-
nism of action is not fully understood but it appears to be a
DNAdamaging agent.48
• Purine analogues (deoxycoformycin, 2-chlorodeoxyadeno-
sine, fludarabine): cytotoxic, immunosuppressive agents.49–52
9.2. Biological response modifiers
BRMs used to treat MF/SS include:
9.2.1. Interferon (IFN)-a
The use of systemic IFN-a in cutaneous lymphomas was first
reported by Bunn and colleagues53 IFN-a is a type I IFN thatbinds to the type I IFN receptor, which is expressed in several
different tumour cell types.54 IFN-a appears to act via a num-
ber of different mechanisms, including cell cycle regulation,
oncogene suppression, and modulation of cell adhesion.54
Various treatment doses have been used, ranging from 3 mil-
lion units (MU) three times per week to 36 MU per day,
although current practice is to start at 3 MU/day and, if toler-
ated, increase to approximately 15 MU/day.3,7,16 Side-effects
include elevated transaminases, leukopenia, and thrombocy-
topenia.15 A dose-related flu-like syndrome is the most
common reason for discontinuation, and the cause of dose-
limiting toxicity.55,56 This side-effect is observed in most pa-
tients but is alleviated by dose reduction.56,57
9.2.2. Retinoids
Retinoids are derivatives of vitamin A that appear to modu-
late cell proliferation and differentiation in several different
neoplasms.3 In MF, these effects extend to epithelial cells
and possibly immunoregulation of mononuclear skin infil-
trates.7 In in vitro studies, 13-cis-retinoic acids induced cellu-
lar differentiation, apoptosis, and DNA fragmentation in
sensitive T-cell lines.58 Retinoids also exhibit immunoadju-
vant properties.59 Commonly used retinoids are acitretin
and isotretinoin; typical starting doses are 25–50 mg/day
and 1 mg/kg/day, respectively.15 Acitretin is a metabolite of
etretinate, which has also been used as therapy for MF.60,61
Retinoids are highly teratogenic.59,60 The most frequently ob-
served side-effect is drying of the skin and mucous mem-
branes, although elevated triglyceride levels are also a
common occurrence.3
9.2.3. Rexinoids
Over the last decade, many of the effects of the retinoids
have been shown to be mediated by their interaction with
a family of nuclear receptors, the retinoic acid receptors
(RARs).62 The retinoid X receptors (RXRs) are a second fam-
ily of nuclear receptors that also bind retinoic acid deriva-
tives, although they differ structurally and functionally
from the RARs.62 The ligand specificity of these receptor
families is also distinct. Bexarotene is highly selective for
the RXRs, and was the first ‘rexinoid’ to undergo clinical
development.63–65 The drug has received EMEA approval in
Europe for the treatment of skin manifestations in advanced
CTCL.66 Although the precise mechanisms are unknown,
in vitro studies have shown that bexarotene can inhibit
growth in tumour cell lines and cause in vivo tumour
regression in animal models: the drug also stimulates apop-
tosis.63,67 Bexarotene is usually administered at 300 mg/m2/
day and treatment is continued indefinitely in patients
who respond.15,16,68 Bexarotene causes severe central hypo-
thyroidism with high frequency, associated with marked
reductions in serum concentrations of thyroid-stimulating
hormone and thyroxine. During treatment, patients should
be monitored for thyroid function and for hypertriglyceride-
mia.15,16,63 Most patients will require concomitant treatment
with a lipid-lowering agent.16,68 Gemfibrozil is contraindi-
cated in this regard because it increases plasma concentra-
tions of bexarotene, presumably due to inhibition of
cytochrome P450 3A4, which, in turn, results in a paradoxi-
cal elevation of triglycerides.15,63,68
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Denileukin diftitox is a recombinant fusion protein compris-
ing diptheria toxin fragments and interleukin (IL)-2 se-
quences.15,69 Denileukin diftitox selectively interacts with
the high-affinity IL-2 receptor (IL2R), resulting in internalisa-
tion of the diptheria toxin moiety, inhibition of protein syn-
thesis, and cell death.15,69 The drug is typically administered
for 5 consecutive days at 9 or 18 lg/kg/day for up to eight
21-day cycles, but only in patients with neoplastic T cells
expressing the high-affinity IL2R.15,69 In this regard, neoplas-
tic cells from patients should be tested for CD25 (the a subunit
of the IL2R) expression prior to initiation of therapy, although
CD25-negative tumours may respond through binding of the
drug to bc-IL2R.69 Approximately one-quarter of patients in
clinical trials developed a ‘vascular leak’ syndrome character-
ised by the presence of two or more of the following: hypoten-
sion, oedema, hypoalbuminemia.69,70 Denileukin diftitox
should be avoided in patients with poorly controlled hyper-
tension, heart failure, or impaired renal or hepatic function.15
Furthermore, the prevalence of antibodies to diptheria toxin
or denileukin diftitox increased from 40% at baseline to nearly
100% after two cycles. There was no apparent relationship be-
tween the presence of antibodies and the likelihood of re-
sponse.70 Patients who received steroid pretreatment
showed an overall decrease in the number of adverse events
and a significant reduction in the number of grade 3/4
events.71 Steroid pretreatment was also correlated with an in-
crease in the overall response rate(ORR): 60% of patients re-
sponded to therapy compared with 30% in the original
phase III trial.71,72
10. Other treatment modalities
10.1. Immunotherapy
Alemtuzumab is a humanised recombinant IgG1j monoclo-
nal antibody with human Fc and V region framework se-
quences. The complementarity-determining regions are
derived from rodent (rat) gene sequences.73 The antibody is
specific for the CD52 cell surface glycoprotein, which is found
at densities of up to 5 · 105 binding sites/cell on the surface of
normal and malignant B and T cells. However, CD52 does not
appear to be expressed by granulocytes or myeloid or ery-
throid bone marrow cells.73 Alemtuzumab is usually adminis-
tered at a dose of 30 mg intravenously three times per week,
following an initial dose-escalation phase, for up to 12
weeks.30,74 In studies in patients with MF/SS to date, the most
common adverse events were opportunistic infections and
neutropenia, which can be severe.30,74 Recently, Lenihan and
colleagues suggested that severe cardiotoxicity may be a sig-
nificant complication of alemtuzumab treatment in MF/SS.75
10.2. Extra-corporeal photoimmunotherapy
The use of ECP was first reported in 1987 by Edelson and col-
leagues76 In this procedure, peripheral blood leukocytes are
harvested, mixed with 8MOP, exposed to UV radiation, and
then returned to the patient.15,77 In the earlier studies,
8MOP was administered orally, but this practice has now been
replaced by ex vivo admixture of 8MOP prior to UV adminis-tration.15,77 The procedure has been described in detail by
Knobler and Jantschitsch77 ECP is usually performed on two
successive days every 4 weeks.8,15 The schedule is generally
continued for up to 6 months in order to assess response:
maintenance therapy is tailored according to disease course.
In general ECP is well tolerated, although patients with a his-
tory of heart disease require careful monitoring due to chang-
ing fluid volumes.15,77
11. Recommendations from the workshop
meeting of the EORTC Cutaneous Lymphoma
Task Force
These guideline recommendations are intended for MF/SS
and may not be appropriate for other CTCLs. They are laid
out by disease stage and subdivided by treatment stage (first-
or second-line).
12. MF: stages IA, IB, and IIA
12.1. First-line recommendations
12.1.1. Expectant policy
Patients with stage IA disease have a normal life expec-
tancy.78,79 For this reason, ‘Expectant Policy’ is a legitimate
management option for patients with this early disease stage.
However, this strategy must incorporate careful monitoring.
Kim and colleagues, in a retrospective cohort analysis, noted
that long-term survival in 122 patients with stage IA disease
was similar to that of an age-, sex- and racematched control
population.78 The median survival of the cohort had not been
reached after 32.5 years of follow-up, and only 2% of patients
had died within that period.78 Zackheim and colleagues re-
viewed survival in 489 patients with CTCL presenting with
disease stage I–IV, and noted that the majority of patients
with CTCL do not die of their disease.79 Only 15–20% of pa-
tients had died over a 10-year follow-up period. In a multicen-
tre, retrospective cohort analysis, van Doorn and colleagues
estimated that the respective risks of disease progression at
5 and 10 years were 4% and 10%, respectively, for stage IA dis-
ease, 21% and 39% for stage IB disease, 32% and 60% for pa-
tients with skin tumours, and 70% at both 5 and 10 years
for patients with stage III disease.28
12.1.2. Skin-directed therapy
12.1.2.1. PUVA. There have been numerous studies on the
effects of PUVA therapy in MF, most of which have been retro-
spective analyses. However, Stadler and colleagues reported
that IFN-a combined with PUVA was significantly superior to
IFN-a plus acitretin.80 In one of the earlier reports, Ho¨nigs-
mann and colleagues reported that PUVA could induce CRs
in stage IA and IB disease.81 Fifty-five percent of patients with
stage IA and 39% with stage IB disease remained disease-free
over a mean follow-up of 44 months. The authors also re-
ported that 5 of 9 patients with stage IA and 10 of 26 with
stage IB disease remained in continuous remission for as long
as 79 months following a single PUVA treatment. These re-
sults indicate that PUVA can induce long-lasting remissions
in early disease without ongoing maintenance therapy. Roupe
and colleagues reported follow-up on 24 patients with early
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disease achieved a CR: half of these patients were still in CR
after a follow-up of 3–18 years. Similarly, Herrmann and col-
leagues reported an ORR of 95% and a CR rate of 65% in a ser-
ies of 82 patients, of whom 83% had stage IA or IB MF.83 In
addition, Molin and colleagues reported a CR rate of 58% in
51 patients with T1 or T2 disease.84 Thus, there is good overall
evidence that PUVA is an effective treatment in early-stage
MF. As noted above, maintenance treatments do not prevent
relapse and should therefore be avoided in order to minimise
total dose and the ensuing risk of squamous cell carci-
noma.16,40 The most common side-effect with methoxsalen
alone is nausea, which occurs in approximately 10% of pa-
tients.38 A mild, transient erythema after PUVA therapy is
an expected side-effect. The peak erythematous reaction usu-
ally occurs about 48 h after methoxsalen ingestion. Pruritus
also occurs in approximately 10% of patients, however, sys-
temic adverse reactions have not been reported.38 As noted
above, PUVA therapy was associated with an increased risk
of non-melanoma skin cancer in a large prospective trial in
patients with psoriasis, although a similar study has not been
conducted in patients with MF.16 Despite the established effi-
cacy of PUVA in early-stage disease, it remains unclear
whether PUVA can improve overall survival.16
12.1.2.2. UVB. Ramsay and colleagues initially reported a CR
rate of 71% in 35 patients with early-stage CTCL treated with
UVB.85 However, although 83% of patients with only patch-
stage disease achieved remission, none of the patients with
plaque-stage disease attained a remission. Clark and col-
leagues reported a CR in 6 of 8 patients treated with narrow-
band UVB.86 Gathers and colleagues assessed the response of
24 patients with stage IA or IB MF to narrowband UVB photo-
therapy over a mean follow-up of 29 weeks.87 Thirteen pa-
tients (54%) achieved a CR, with histological clearing in 9 of
10 patients who underwent a repeat biopsy. Seven patients
(29%) achieved a PR and there was no response in 4 patients
(17%). However, 4 of the patients with a CR experienced re-
lapse following treatment discontinuation. Diederen and col-
leagues compared narrowband UVB to PUVA therapy in 56
patients with stage IA and IB MF.41 Twenty-one patients were
treated with UVB and 35 with PUVA. CRs were obtained in 81%
of patients treated with UVB and in 71% of those treated with
PUVA. Corresponding PR rates were 19% and 29%, respec-
tively. Mean PFS was 24.5 months for UVB and 22.8 months
for PUVA. The EORTC Workshop meeting recommended that
UVB treatment should be used only for patch lesions, and
not for plaques, as UVB is known to only reach the superficial
layers of the skin.
12.1.2.3. Topical corticosteroids. Zackheim and colleagues
evaluated responses to topical corticosteroids (predominantly
class 1) in 51 patients with T1 MF and 28 with T2 MF. Seventy-
five patients had patch-stage disease.88 Topical corticoste-
roids were applied for 2–3 months and for a further month
after the lesions cleared. Patients were followed up for a med-
ian of 9 months. CRs and PRs were obtained in 32 (63%) and 16
(31%) patients with T1 disease, respectively. Comparable re-
sults for patients with T2 MF were 7 (25%) CRs and 16 (57%)
PRs.79 Post-treatment biopsies were obtained from 7 of the39 patients who achieved clinical clearing of their lesions;
all 7 biopsies also showed histological clearance. Reversible
depression of serum cortisol occurred in 10 patients (13%)
and localised, reversible skin atrophy was noted in 1 pa-
tient.88 These data indicate that class 1 corticosteroids can
be an effective treatment for patch-stage MF.
12.1.2.4. Localised radiotherapy. Micaily and colleagues clas-
sified 18 of 325 incoming patients with MF as having unile-
sional MF.89 Patients received 30.6 Gy in daily fractions of
1.8–2.0 Gy, except for 2 patients treated with 40 Gy or 22 Gy.
All treated lesions cleared completely within 4–8 weeks of
radiotherapy completion, with a 100% CR rate. Two relapses,
confined to the skin, occurred at a median follow-up of 43
months, although at different sites to the original lesions. Re-
lapse-free and overall survival at 10 years were 86% and 100%,
respectively.89 Orthovoltage radiotherapy can also be used at
a low dose to treat individual plaques or tumours, with a
higher rate of recurrence with doses below 30 Gy.46
12.1.2.5. TSEB. As noted earlier, EORTC consensus guide-
lines for the use of TSEB in MF have been published else-
where.43 Jones and colleagues reported a CR rate of 95% in
123 newly diagnosed patients with stage IA MF treated with
31–36 Gy TSEB.42 PFS was 35% at 15 years, however, PFS in pa-
tients with stage IB disease was only 10% at 10 years. In a ret-
rospective review of patients at their centre, Jones and
colleagues noted that the overall probability of CR was
approximately 90% in early disease and 60% in advanced dis-
ease.42 A meta-analysis of several uncontrolled and retro-
spective studies has established that CR rates are dependent
on disease stage, skin surface dose, and electron beam en-
ergy.90 CR rates are 96% in stages IA, IB, and IIA, 36% in stage
IIB, and 60% in stage III. Increased skin surface dose (32–36 Gy)
and higher energy beams (4–6 MeV) were significantly associ-
ated with higher CR rates.30 Following administration of TSEB,
all patients can be expected to develop complete temporary
alopecia and nail stasis, although nail loss is rare.42,43 Minor
erythema may develop in normal skin, although a more se-
vere reaction, perhaps even desquamation, may occur in skin
previously exposed to UV radiation.43 Approximately 50% of
patients experience minor oedema of the hands and feet,
which may be exacerbated by physical activity during TSEB
therapy or underlying conditions such as diabetes.43 Long-
term effects, including skin infections requiring systemic
therapy, are rare, and corneal tears due to internal eye shields
occur in <1% of patients.43 Men may become infertile, so
sperm banking should be considered if fertility is a concern.
The EORTC Workshop meeting recommended that TSEB
should be administered on no more than three occasions to
each patient.
12.1.2.6. Topical HN2. There have been no randomised clini-
cal trials on the use of topical HN2 in MF/SS. Hoppe and col-
leagues reported results from a retrospective series of 123
patients with MF who were treated with topical HN2.
33 Re-
sponse rates depended on the degree of skin involvement.
CR rates and ORRs were, respectively, 51% and 88% for T1 dis-
ease, and 26% and 69% in T2 disease.33 In a cohort of 117 pa-
tients, Ramsay and colleagues reported that the probability of
Table 4 – Recommendations for first-line treatment of MF
(stages IA, IB, and IIA)a
Recommended treatments Grade of
ecommendation
level of evidence
References
‘Expectant Policy’ C 4 [28,78,79]
SDT PUVA C 4 [16,40,81–84]
UVB (patches only) C 4 [41,85–87]
Topical corticosteroids C 4 [88]
Localised radiotherapy C 4 [89]
TSEB (63 treatments) C 4 [30,42,43,90]
HN2 C 4 [32,34,91]
BCNU C 4 [30,92,93]
a The order of recommended treatments is based on the consen-
sus opinion of the authors. The individual choice of the appro-
priate therapy can differ and will depend on clinical presentation
and treatment availability.
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with stage I disease and 45% for patients with stage II dis-
ease.34 Furthermore, the time to remission was shorter for pa-
tients with stage I than stage II disease.34 Vonderheid and
colleagues have reported a 20% CR rate in 331 patients treated
with topical HN2.
91 The duration of responses was between 4
and 14 years. The Stanford Group has recently updated their
retrospective experience with topical HN2: 203 patients with
stage I–III disease received HN2 as first-line therapy.
32 The
ORR was 83% and the CR rate 50%. Median time to CR was
10 months for patients with T1 disease and 19 months for
those with T2 disease. Most of the patients achieving an ini-
tial CR received only HN2 throughout the follow-up period.
32
Progression-free survival (PFS) was 92% and 85% at 5 and 10
years, respectively, in patients with T1 disease. The differ-
ences between these studies can probably be attributed to
the inclusion of different proportions of patients at each dis-
ease stage. The treatment was generally well tolerated. In the
study by Ramsay and colleagues, 68 patients (58%) developed
a delayed hypersensitivity reaction but only 1 patient discon-
tinued therapy as a result.34 Furthermore, the Stanford Group
reported that fewer than 10% of patients experienced contact
hypersensitivity, although this appears to be more common
with the aqueous preparation than with the ointment.32,33
The reported incidence of secondary cutaneous malignancies
was 4–11%, although this may not be due to topical HN2 ther-
apy.32,33 These results indicate that topical HN2 is an effective
first-line treatment for early-stage MF.
12.1.2.7. Topical BCNU. Most of the studies on the treatment
of patients with MF with topical BCNU have been published
by the University of California at San Francisco Group.92–94
No randomised controlled trials have been reported. Zack-
heim and colleagues retrospectively reported the results of
143 patients treated over a 15-year period.92 A CR rate of
86% was achieved in patients with T1 disease, and a 48% CR
rate was seen in those with T2 disease. In a subsequent re-
port, the same group noted that, at 36 months following initi-
ation of treatment in 172 patients, 92% of patients with stage I
and 64% with stage II disease were in CR or PR.93 The major
toxicity is delayed bone marrow suppression, and blood
counts should be monitored for at least 6 weeks after BCNU
therapy.95 In addition, bone marrow toxicity is cumulative
and dose adjustments should be based on nadir counts after
the previous dose.95 However, bone marrow suppression in
the studies described above, was uncommon.93 Zackheim
and colleagues, in their series of 143 patients, reported that
mild haematopoietic depression occurred in less than 10%
of patients.92 However, others have reported bone marrow
suppression rates of 30%.30 The most common side-effect
was an erythematous reaction, although no secondary cuta-
neous malignancies occurred.92,93 Gastrointestinal toxicity
has been frequently noted, usually within 2 h of BCNU admin-
istration, and renal dysfunction has been reported in patients
exposed to large cumulative doses.95 BCNU appears to be clin-
ically effective, although comparative trials between HN2 and
BCNU are needed.30
12.1.2.8. Chemotherapy. Although chemotherapy can induce
responses in MF, such responses are usually short-lived andoffer no demonstrable improvement in survival.16,96,97 Kaye
and colleagues conducted a randomised trial comparing TSEB
combined with chemotherapy (cyclophosphamide, doxorubi-
cin, etoposide, vincristine) with SDT.96 The combination ther-
apy achieved a significantly higher CR rate but at the expense
of considerable toxicity. Importantly, after a median follow-up
of 75 months, there was no difference between the treatment
groups in terms of PFS or overall survival.96 Hence, aggressive
treatment with radiation and chemotherapy does not im-
prove prognosis in patients with early-stage MF compared
with those treated with standard SDT.96 The EORTC Work-
shop meeting recommended that systemic chemotherapy
should not be used at this disease stage.
Recommendations for first-line treatment of MF (stages IA,
IB and IIA) are summarised in Table 4.
12.2. Second-line recommendations
12.2.1. Systemic therapies
12.2.1.1. Oral bexarotene. Oral bexarotene in the treatment
of refractory, early-stage CTCL was evaluated in a phase II/
III trial, in which 58 patients were treated with doses varying
from 6.5 to 650 mg/m2.65 All but one of the patients had stage
IA, IB, or IIA disease. At the optimal dose of 300 mg/m2, 54%
(n = 15) of patients responded, with a CR rate of 7% (including
clinical CR [CCR]). Response rates were similar across disease
stages. At the 300 mg/m2 dose, the median response duration
had not been reached after 73 weeks and only 2 of 15 patients
had relapsed disease.65 In this trial, reversible and treatable
adverse events included: hypertriglyceridemia in 46 of 58 pa-
tients (79%), hypercholesterolemia in 28 patients (48%), cen-
tral hypothyroidism in 23 patients (40%), and leukopenia in
16 patients (28%).65 No cases of drug-related neutropenic fe-
ver, sepsis or death occurred. Pancreatitis occurred in 3 pa-
tients taking bexarotene 300 mg/m2/day who had
triglyceride levels >14.7 mmol/L.65 Bexarotene induces lipid
abnormalities in most patients although these can generally
be managed with antilipemic therapy.63 Elevations of liver
function tests (LFTs) have been reported in patients receiving
an initial dose of 300 mg/m2, and both LFTs and thyroid func-
tion should be monitored during therapy. As previously noted,
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rexinoids are teratogenic.63 In conclusion, oral bexarotene is
an effective alternative for patients with refractory, early-
stage CTCL. Bexarotene can also be used topically and is ap-
proved for refractory, early-stage disease in the USA.
12.2.1.2. IFN-a. Monotherapy with IFN-a has been shown to
induce significant responses in patients with MF/SS, includ-
ing responses in previously treated patients.98–101 Vegna and
colleagues administered IFN-a daily to 23 newly diagnosed
patients at doses of 3–18 MU over a period of 12 weeks.99
Responders continued to receive IFN-a at the MTD for 6–9
months. The ORR was 74% and the CR rate was 35%. Olsen
and colleagues treated 22 patients with IFN-a and observed
CRs in 6 patients, with a CR rate of 27% and an ORR of
64%.55 CRs were observed in patients with early (I–IIA) and ad-
vanced disease (IVA); all but 3 patients had received prior
therapy. Ross and colleagues reviewed the results of IFN-a
treatment in 304 patients with CTCL and reported that the
ORR, including CRs, PRs and minor responses, was 70%.102
The authors also noted that fatigue, anorexia, and a flu-like
syndrome were common in IFN-treated patients. Leukocyte
count declined within hours of drug exposure but stabilised
at 40–60% of the normal count. However, recovery occurred
rapidly following cessation of IFN-a therapy. Dose reduction
was necessary in the majority of patients with CTCL receiving
high-dose IFN-a treatment due to flu-like symptoms. At least
one fatal side-effect, severe neutropenic sepsis, has been re-
ported in CTCL, and haematological parameters should be
monitored during therapy.102 Summarising the available evi-
dence, Bunn and colleagues concluded that there is no direct
correlation between the dose of IFN-a and response. The
authors recommend a schedule of 3 MU three times per week
as the optimal regimen.103
12.2.1.3. IFN-a plus retinoids. Knobler and colleagues con-
ducted a pilot study, in which 7 patients with CTCL were trea-
ted with low-dose IFN-a and 13-cis-retinoic acid: 4 of the
patients had received prior treatment.104 Combination ther-
apy resulted in 2 CRs and 2 PRs, which were maintained for
up to 15 months. Dreno and colleagues treated 32 patients
with MF with IFN-a for 3 months.61 Responders continued
on IFN-a alone, whereas non-responders were treated with
IFN-a and etretinate. Twenty of the 25 patients with stage
I–II disease responded; 12 patients with IFN-a alone and 8
with combined therapy. In a study conducted by Stadler and
colleagues, 38% of patients treated with IFN-a plus acitretin
achieved a CR, with an ORR of 60%.80 Zachariae and Thest-
rup-Pedersen treated 11 patients with MF with IFN-a plus
etretinate (n = 7) or IFN-a alone (n = 4).98 Two patients, 1 trea-
ted with IFN-a plus etretinate, achieved a CR and 5 a PR. The
study showed that IFN-a plus etretinate can induce remission
of CTCL. However, it should be noted that response rates ob-
served with IFN-a plus retinoids were similar to IFN-a
monotherapy.
12.2.1.4. Denileukin diftitox. In a phase III trial, of 26 previ-
ously treated patients with tumour stage IIA or less were trea-
ted with denileukin diftitox 9 (n = 14) or 18 lg/kg/day (n = 12).72
Six of the 14 patients treated at the lower dose achieved a re-sponse, with 3 CRs (either CR or CCR). However, CRs only oc-
curred in patients with stage I disease. At the higher dose, 4 of
the 12 patients responded but there was only 1 CR in a patient
with stage IB disease. The median duration of response for all
patients in the study was 6.9 months (range 2.7–46.1).72 In
addition, there was no clear indication of any dose response
relationship. Routine premedication with systemic corticoste-
roids was prohibited in this study. As noted above, approxi-
mately one-quarter of patients in clinical trials developed a
‘vascular leak’ syndrome characterised by the presence of
two or more of the following: hypotension, oedema, hypoal-
buminemia.69,70 In two clinical trials of 143 patients with lym-
phoma, including 105 with CTCL, acute hypersensitivity
reactions occurred in 98 patients (69%).69 Infections occurred
in almost half of the patients receiving denileukin diftitox, of
which 23% were considered severe. In most of these patients
with advanced-stage and/or heavily pretreated CTCL, infec-
tions were considered unrelated to treatment. Almost all
(91%) patients experienced a flu-like syndrome within hours
or days of receiving denileukin diftitox, although in most pa-
tients the symptoms were mild-to-moderate and responded
to appropriate therapy. Gastrointestinal toxicities included
diarrhoea and dehydration. The latter occurred in 9% of pa-
tients, usually concurrent with vomiting or anorexia.69 The
above phase III trial was an open, uncontrolled study but, as
most of the patients had been heavily pretreated, the level
of response suggests a useful role for this drug in patients
with resistant, early-stage disease, but the therapy is cur-
rently not licensed in Europe.30,72
12.2.1.5. Low-dose MTX. There are few published reports
on the use of MTX in MF, even though initial reports ap-
peared more than a quarter of a century ago.106 McDonald
and Bertino administered high-dose intravenous MTX to 11
patients with stage II–III MF.107 Seven patients achieved a
CR, which was maintained with weekly low-dose intrave-
nous MTX. More recently, Zackheim and colleagues reported
a retrospective study, in which 7 of 60 (12%) patients with
patch/plaque MF (T2) attained a CR, and 13 (22%) achieved
a PR.105 Median time to treatment failure (TTF) was 15
months. The incidence and severity of adverse reactions to
MTX therapy are related to the dose and frequency of
administration.108 The most common side-effects include
ulcerative stomatitis, leukopenia, abdominal distress, undue
fatigue and decreased resistance to infection. MTX can also
suppress haematopoiesis and has been associated with gas-
trointestinal toxicity, hepatoxicity, and pulmonary symp-
toms, as well as other organ toxicities.108 In the study by
Zackheim and colleagues described above the medium
weekly dose was 25 mg with maximum doses up to 75 mg;
side-effects were responsible for treatment failure in 6 (9%)
of the total cohort of 69 patients.106
12.2.2. Systemic therapies combined with SDT
12.2.2.1. IFN-a plus PUVA. Mostow and colleagues supple-
mented PUVA treatment with low-dose IFN-a in 5 patients
who had previously failed PUVA alone.109 CRs were achieved
in all 5 patients. Kuzel and colleagues reported an ORR of
90%, with 62% CRs, in 39 patients treated with IFN-a plus
PUVA.110 Nineteen of the patients were in MF stage IB or IIA,
Table 5 – Recommendations for second-line treatment of
MF (stages IA, IB, and IIA)a
Recommended
treatments
Level of
evidence
References
Systemic therapies
Oral bexarotene B 1b [65]
IFN-a monotherapy B 2b [55,99,100,102,105]
IFN-a tretinoids B 1b [61,80,98,104]
Denileukin diftitox B 1b [30,72]
Low-dose MTX C 4 [106]
Systemic therapies + SDT
IFN-a + PUVA B 1b [80,109,110,113]
Retinoids + PUVA C 4 [114]
Bexarotene + PUVA C 4 [115]
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treated a series of 16 patients with MF with IFN-a (9 MU) plus
PUVA, 3 J/cm2.111 IFN-a was continued indefinitely following
remission and PUVA was discontinued after a minimum of 2
months. Ten patients achieved a CR and 3 achieved a PR. Over
a 10- to 40-month follow-up period, 4 patients developed pro-
gressive disease. A further 3 patients suffered local recur-
rences but repeat treatment maintained the remission.111 In
a series of 25 patients (19 with stage I disease), Rupoli and col-
leagues reported final response rates of 76% (CR) and 20%
(PR).112 PFS was 82% at 12 months and 62% at 24 months. Chi-
arion-Sileni and colleagues conducted a phase II trial, in
which patients with CTCL were given IFN-a (12 MU) three
times per week following initial dose escalation.113 PUVA
was then initiated three times per week and continued indef-
initely at 2- to 4-week intervals. Sixty-three patients were
enrolled, of whom 46 were in disease stage IIA or earlier. Forty-
seven (75%) patients achieved a CR and 10% achieved a PR.113
Ten of the 63 patients had received prior therapy, although
their disease stage was not reported. Nine patients had dis-
ease relapse at a median of 12 months, of whom 8 were re-
treated: 5 of these patients attained a second CR with IFN-a
plus PUVA. Collectively, these results indicate that IFN-a plus
PUVA can be an effective second-line treatment, although
superiority of IFN-a plus PUVA over PUVA alone is not clearly
documented.
12.2.2.2. Retinoids plus PUVA. Thomsen and colleagues re-
ported responses in 69 patients with plaque-stage MF treated
with either PUVA or PUVA plus oral retinoids.114 CRs were ob-
tained in 73% and 72% of patients, respectively.114 Further-
more, in the combination treatment group, remissions were
obtained with a lower UVA dose.
In one of the few prospective, randomised trials conducted
in CTCL, Stadler and colleagues performed a multicentre
comparison of IFN-a plus PUVA versus IFN-a plus acitretin.80
Ninety-eight patients were enrolled, although only 82 were
evaluable; 40 for IFN-a plus PUVA, and 42 for IFN-a plus acitre-
tin. In the former group, 35 of the 40 patients had stage IA–IIA
disease, whereas in the IFN-a plus acitretin group, the propor-
tion was 39 of 42 patients. Seventy percent of patients in the
IFN-a plus PUVA group achieved a CR compared with 38% in
the IFN-a plus acitretin group. Respective ORRs were 80%
and 60%. IFN-a plus PUVA resulted in a significantly improved
response rate compared with IFN-a plus acitretin. Twenty-
four of 40 (60%) patients in the IFN-a plus PUVA group had re-
ceived prior treatment compared with 34 of 42 (81%) in the
IFN-a plus acitretin group, a statistically significant difference
that arose from excluding non-evaluable patients after the
initial randomisation. However, the superiority of IFN-a plus
PUVA was still evident in an intent-to-treat analysis
(P < 0.05). In short, this trial provided evidence of a marked
improvement provided by IFN-a plus PUVA compared with
IFN-a plus acitretin, including use as second-line treatment.80
12.2.2.3. Bexarotene plus PUVA. Singh and Lebwohl con-
ducted a retrospective chart review in 8 patients (stage IA–
IIB) with CTCL that had recurred following monotherapy with
various agents, including TSEB, IFN-a, PUVA and topical ste-
roids: the patients were then treated with PUVA plus bexaro-tene.115 A response was achieved in all 8 patients, including 5
CRs.115 An EORTC-sponsored phase III trial is currently
recruiting patients for a comparison between PUVA alone
and PUVA plus bexarotene.116
Recommendations for second-line treatment of MF (stages
IA, IB and IIA) are summarised in Table 5.
12.3. MF: stage IIB
12.3.1. First-line recommendations
12.3.1.1. PUVA plus IFN-a. In the prospective, randomised,
controlled trial described above, Stadler and colleagues re-
ported that PUVA plus IFN-a resulted in CRs in 2 of 9 patients
with stage II disease, and PRs in 3 of 9 patients.80 Unfortu-
nately, these authors did not discriminate between results ob-
tained in patients with stage IIA and stage IIB disease.
Chiarion-Sileni and colleagues included 3 patients with stage
IIB MF in their phase II trial, and reported that CRs were ob-
tained in all disease stages, except in patients with SS.113
However, the investigators did not provide response data by
stage. Jumbou and colleagues reported longterm follow-up
for a cohort of 51 patients with various stages of MF who were
treated with IFN-a.105 Most (35) patients had not received
prior therapy. Of the 30 patients with stage IIB disease, 23
(77%) responded, including 10 (33%) CRs. However, half of
the patients in CR had disease relapse within 1 year.105
12.3.1.2. TSEB and superficial X-irradiation. As mentioned
earlier, a meta-analysis reported CR rates of 36% in patients
with stage IIB disease.90 Superficial irradiation of specific le-
sions achieves a CR in more than 90% of treated tumours.46
TSEB has also been combined with total nodal irradiation.
Micaily and colleagues reported that this procedure resulted
in 100% CRs in 14 patients with stage I–II disease, including
5 with stage IIB disease.117
12.3.1.3. PUVA plus acitretin. Early studies include those of
Hunziker and colleagues and Serri and colleagues118,119 Re-
sults from the study by Thomsen and colleagues have been
described above.114 However, in this study, no patients with
stage IIB disease were included. Thus, the recommendation
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expert opinion and not on published data.
Recommendations for first-line treatment of MF (stage IIB)
are summarised in Table 6.
12.3.2. Second-line recommendations
12.3.2.1. Bexarotene. In the phase II/III trial of bexarotene in
advanced CTCL, the ORR was between 27% and 48%, depend-
ing on the criteria used.120 Forty-one patients with stage IIB
disease were treated at 300 mg/m2/day, and achieved a re-
sponse rate of 57% for skin lesions.
12.3.2.2. Chemotherapy. Monotherapy and combination
therapy protocols are recommended. A phase II trial of
gemcitabine monotherapy achieved an ORR of 70% (10%
CR, 60% PR) in 30 previously treated patients with T3 or
T4 disease.121 Kurzrock and colleagues assessed the efficacy
of pentostatin (deoxycoformycin) in a study that included 6
patients with tumour-stage MF who had received prior
therapy.49 One patient achieved a CR and 3 attained a PR.
Trautinger and colleagues assessed the efficacy of low-dose
2-chlorodeoxyadenosine in 8 patients with > stage IIB MF.50
Two patients achieved longlasting PRs (20 and >21 months)
and 1 patient had a 14-month period of stable disease.50
Bunn and colleagues reviewed several studies using chemo-
therapy in patients with advanced MF and SS (stage IIB on-
wards).103 A total of 331 patients were treated with various
combination chemotherapy regimens in these studies. CRs
or PRs were obtained in 269 patients (81%), with median re-
sponse durations ranging from 5 to 41 months. Response
rates (CR + PR) in the individual studies ranged from 57%
to >90%, although several of the studies had very low pa-
tient numbers.103 Wollina and colleagues evaluated the effi-
cacy of single-agent pegylated liposomal doxorubicin as
second-line chemotherapy in patients with CTCL.122 Of 34
patients treated with pegylated liposomal doxorubicin, 15
achieved a CR and 15 a PR, with an ORR of 88.2%. Overall
survival was 17.8 ± 10.5 months, event-free survival was
12 ± 9.5 months and disease-free survival was 13.3 ± 10.5
months.122
12.3.2.3. Denileukin diftitox. The phase III trial described
earlier included 19 patients with stage IIB MF who had re-
ceived a median of 5 prior therapies.72 One PR was achieved
among the 9 patients treated with denileukin diftitox 9 lg/
kg, whereas, of the 10 patients treated with 18 lg/kg, 2
achieved a CR and 3 attained a PR. Although these data sug-
gest some dose dependency, the results did not reach statisti-
cal significance (P = 0.07). Thus, for patients with stage IIBTable 6 – Recommendations for first-line treatment of MF
(stage IIB)a
Recommended treatments Level of
evidence
References
PUVA + IFN-a B 1b [80,109,110,113]
TSEB and superficial X-irradiation C 4 [90,46,117]
Retinoids + IFN-a B 1b [61,80,98,104]
PUVA + retinoids D 5 [114]disease, the ORR across both dose levels was 32% (6/19
patients).
Recommendations for second-line treatment of MF (stage
IIB) are summarised in Table 7.
12.4. MF: stage III
12.4.1. First-line recommendations
12.4.1.1. PUVA plus IFN-a. Several relevant studies have al-
ready been described.109–112 In the trial conducted by Chia-
rion-Sileni and colleagues, described above, 12 of 63 patients
had stage III disease, and the authors noted that CRs were
achieved in all disease stages, except in patients with SS.113
Unfortunately, the response data were not reported by disease
stage, or by prior treatment status. Roenigk and colleagues re-
ported results from a phase I trial with PUVA plus IFN-a in 15
patients with MF disease stages IB–IVB. CRs were achieved in
12 of 15 patients, and PRs in 2 patients.123
12.4.1.2. IFN-a. In one of the earlier studies, Bunn and col-
leagues reported results of a phase II trial with IFN-a therapy
in 20 patients with refractory MF.56 Five patients had general-
ised plaque disease, 10 had cutaneous tumours, and 5 had
generalised erythroderma. Nine patients responded (ORR
45%) and 2 patients achieved a CR. In the study by Olsen
and colleagues, referred to earlier, responses were observed
in 2 of 3 patients with stage III disease.55
12.4.1.3. MTX. In a retrospective study of 29 patients with
erythrodermic CTCL, Zackheim and colleagues observed a
CR rate of 41% and a PR rate of 17%, for a total ORR of 58% fol-
lowing MTX treatment.124 Median TTF was 31 months. In
addition, McDonald and Bertino reported that 7 of the 11 pa-
tients with stage II–III MF achieved a CR in their study de-
scribed above.107
12.4.1.4. TSEB. According to guidelines and as discussed
above, Jones and colleagues combined TSEB with oral etreti-
nate but, after a median follow-up of 2 years, the relapse-free
survival rate in patients who achieved a CR was similar to
that in stage-matched controls.125 Jones and colleagues have
recently reviewed the use of TSEB in combination with other
modalities.42
12.4.1.5. Topical HN2. In a retrospective analysis of 117 pa-
tients with MF, Ramsay and colleagues reported that the prob-
ability of achieving remission within 2 years of initiating HN2
treatment was 49% in patients with stage III disease. The
median time to remission was 39 months.34Table 7 – Recommendations for second-line treatment of
MF (stage IIB)a
Recommended
treatments
Level of
evidence
References
Bexarotene B 2b [120]
Chemotherapy C 4 [49,50,103,121]
Denileukin diftitox B 1b [72]
Table 9 – Recommendations for second-line treatment of
MF (stage III)a
Recommended
treatments
Level of
evidence
References
Bexarotene B 2b [120]
Chemotherapy C 4 [15,16,121,103,51,130]
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colleagues, a series of studies have confirmed the efficacy of
ECP in treating CTCL.76 Reported ORRs range from 31% to
80%, with 0–25% CRs.77 Suchin and colleagues observed a
75% ORR in a retrospective cohort study, and Gottlieb and col-
leagues reported a CR rate of 25% and a PR rate of 46% from a
retrospective chart review of 28 patients with stage III or IV
disease.126,127 In addition, ECP has minimal side-effects.77,128
Zic and colleagues also reported a CR rate of 25% and PR rate
of 25% in a cohort of 20 patients.128 Long-term follow-up of
this cohort showed a median survival of 96 months. In addi-
tion, early response after 6–8 months of ECP therapy was pre-
dictive of long-term outcome.128
12.4.1.7. PUVA plus acitretin or bexarotene. The pertinent
literature and the EORTC-sponsored phase III clinical trial
have been described above.114,116 As mentioned above, there
is no published evidence as yet for the efficacy of these com-
bination regimens in stage III disease.
Recommendations for first-line treatment of MF (stage III)
are summarised in Table 8.
12.4.2. Second-line recommendations
12.4.2.1. Bexarotene. In the phase II/III trial of bexarotene in
advanced CTCL 29 patients with stage III were treated.120 The
ORR was 32% and 40% depending on the initial dose (300 mg/
m2/day versus > 300 mg/m2/day, respectively).
12.4.2.2. Chemotherapy. Many different chemotherapeutic
agents have been assessed in the treatment of CTCL, in both
single-agent and combination protocols.15,16,103 However, re-
sponse durations are relatively short.16,129 As mentioned ear-
lier, gemcitabine monotherapy achieved an ORR of 70% in 30
previously treated patients with T3 or T4 disease.121 Kuzel and
colleagues conducted a phase II trial of 2-chlorodeoxyadeno-
sine in 21 patients with MF disease stage IB–IVB: among the 5
patients with stage III disease, 1 achieved a CR and 1 achieved
a PR.51 One of 8 patients with stage IVA disease achieved a CR;
there were no PRs, and neither of the 2 patients with stage IVB
disease responded. Tirelli and colleagues treated 16 patients
with advanced CTCL (T3, T4 and extra-cutaneous disease)
with CVP (cyclophosphamide, vincristine, and prednisone).130
A 50% ORR was achieved and 4 patients attained a CR. Fierro
and colleagues assessed the efficacy of VICOP-B (idarubicin,
etoposide, cyclophosphamide, vincristine, prednisone, bleo-
mycin) in 25 patients with advanced CTCL (stages IIB andTable 8 – Recommendations for first-line treatment of MF
(stage III)a
Recommended
treatments
Level of
evidence
References
PUVA + IFN-a B 1b [109–113,123]
IFN-a B 2b [55,56,99,102]
MTX C 4 [123]
TSEB/X-irradiation C 4 [42]
HN2 or BCNU C 4 [35]
ECP C 4 [76,77,126–128]
PUVA + retinoids D 5 [114]IV).131 An ORR of 84% was achieved in patients with MF, with
a median duration of 8.7 months.131
Recommendations for second-line treatment of MF (stage
III) are summarised in Table 9.
12.5. MF: stages IVA–IVB
It should be recognised that treatment at this stage is pallia-
tive. Therapy should be chosen to be effective and have a
favourable side-effect profile. Treatment options include all
of the various modalities previously mentioned. Patients
should be entered into clinical trials wherever possible.
Recommendations for treatment of MF (stage IVA–IVB) are
summarised in Table 10.
12.6. Se´zary syndrome
12.6.1. First-line recommendations
12.6.1.1. ECP. A substantial proportion of patients in the
original study by Edelson and colleagues had SS. Following
oral administration of methoxsalen, a lymphocyte-enriched
fraction of the patient’s blood was exposed to 1–2 J/cm2
ex vivo and then returned to the patient.76 Twenty-seven of
37 patients with resistant CTCL responded to the treatment,
with an average decrease in cutaneous involvement of 64%
after a mean period 22 weeks.76 In the study by Suchin and
colleagues, 89% of a consecutive sample of 47 patients had
circulating malignant T cells.126 ECP monotherapy resulted
in a 75% ORR and median survival of 66 months. The authors
also reported an increase in the ORR and survival duration
when ECP was combined with immunostimulatory agents
such as IFN-a. Furthermore, Gottlieb and colleagues, reported
a CR rate of 25% and a PR rate of 46% from a retrospective
chart review of 28 patients with stage III or IV disease.127
The majority of these patients also had circulating malignant
T cells. In a retrospective analysis of data from 23 patientsTable 10 – Recommendations for treatment of MF (stages
IVA–IVB)a
Recommended
treatments
Level of
evidence
References
Chemotherapy C 4 [15,16,121,103,51,130,131,133]
TSEB and/or
X-irradiation
C 4 [30,42,43,90]
Bexarotene B 2b [120]
Denileukin diftitox B 1b [72]
IFN-a C 2b [55,56,99,102]
Alemtuzumab C 2b [74,132]
Low-dose MTX C 4 [124]
Table 11 – Recommendations for first-line treatment of
SSa
Recommended
treatments
Level of
evidence
References
ECP C 2b [76,77,126,127,134,135]
IFN-a C 2b [55,56,99,101,102]
Denileukin diftitox B 1b [72]
Chlorambucil + prednisone C 4 [136]
Table 12 – Recommendations for second-line treatment
of SSa
Recommended
treatments
Level of
evidence
References
Bexarotene B 2b [120]
Chemotherapy C 4 [52,130,137]
Alemtuzumab C 2b [67,135]
MTX C 4 [138]
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authors noted that responders were more likely to have a
higher baseline lymphocyte count and a higher proportion
of Se´zary cells in the total leukocyte count than non-respond-
ers, whereas others have reported optimal responses in pa-
tients with a lower CD4/CD8 ratio.134,135 The use of ECP to
treat MF/SS, including ECP combination modalities, has been
recently reviewed by Knobler and Jantschitsch.77
Other recommended treatment options include immuno-
therapy, BRMs, and chlorambucil plus prednisone.136 The per-
tinent studies have been discussed above and are cited in
Table 11.
12.6.2. Second-line recommendations
12.6.2.1. Bexarotene. In the phase II–III trial of bexarotene in
patients with advanced MF/SS, the response rate in patients
with SS was 24% (4 of 17 patients).120
12.6.2.2. Chemotherapy. In addition to the studies cited ear-
lier, Akpek and colleagues undertook a phase II study to as-
sess the efficacy of the EPOCH (etoposide, vincristine,
doxorubicin, bolus cyclophosphamide, oral prednisone) regi-
men.137 Fifteen patients with advanced, refractory CTCL were
treated, including 6 with SS. The ORR was 80%, with 27% CRs.
Two of the 6 patients with SS had complete clearance of circu-
lating Se´zary cells. The protocol was deemed to have accept-
able toxicity. However, Fierro and colleagues did not observe
any responses in patients with SS treated with the VICOP-B
regimen.131 Scarisbrick and colleagues studied the efficacy
of fludarabine plus cyclophosphamide in 12 patients with ad-
vanced CTCL; 8 patients had SS.52 Five of 8 patients with SS
responded, including 1 CR, but bone marrow toxicity was sig-
nificant. The authors concluded that, although this protocol
might offer clinical benefit, there did not appear to be any evi-
dence of improved survival.52
12.6.2.3. Alemtuzumab. Lundin and colleagues conducted a
phase II study of alemtuzumab in 22 patients with advanced
MF/SS.74 The ORR was 55%; 32% of patients achieved a CR
and 23% a PR. Se´zary cells were cleared from the blood in 6
of 7 (86%) patients, and CR in lymph nodes was observed in
6 of 11 (55%) patients.74 Kennedy and colleagues treated 8 pa-
tients with relapsed or refractory advanced-stage CTCL with
alemtuzumab.132 Patients were given alemtuzumab (30 mg)
intravenously three times per week for 12 weeks or until max-
imum response. The ORR was 38%, with 3 patients achieving
a PR, 2 with stable disease and 3 with progressive disease dur-
ing treatment. All patients developed progressive disease
within 4 months of starting alemtuzumab.13212.6.2.4. MTX. Zackheim and colleagues treated 17 patients
with SS with low-dose MTX for up to 5 years (median 22
months).138 Seven patients (41%) achieved a CR and the ORR
was 76%. The estimated 5-year survival rate was 71%.
Recommendations for second-line treatment of SS are
summarised in Table 12.
13. Summary and conclusion
In early-stage MF, SDT represents the most appropriate ther-
apy. Most patients will be able to achieve a short-term clinical
response with recurrent disease for many years and, in the
majority of cases, a normal life expectancy. Therefore, poten-
tially toxic and aggressive therapies should be avoided. Pa-
tients with more advanced stages of MF and patients with
SS have a poor prognosis. In these patients, the absence of
randomised, controlled trials results in a lack of sufficient evi-
dence to provide a basis for a consensus. None of the thera-
pies described so far have a documented impact on disease
outcome. Thus, all patients with late-stage disease should
be entered into appropriate clinical trials. As treatment of
MF/SS is always palliative, maintenance of quality of life
should be at the centre of therapeutic strategies.
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